Table 1.
IFTA + inflammation prevalence estimates
| Study | Population | Biopsy | Time post-Transplant | Prevalence | Definition | Ref |
| Park et al | LD recipients 2000–2007 |
Protocol | 1 year | 20/151 13% |
Mayo | 41 |
| Cosio et al | LD and DD recipients 1998–2001 |
Protocol | 1 year | 53/292 18% |
Mayo | 10 |
| Gago et al | LD and DD recipients 2000–2006 |
Protocol: 151/207, 73% Indication: 56/207, 27.1% |
16.9±15.5 mos (1, 3, 5 years) |
207/795 26% |
Mayo | 42 |
| Gago et al | LD and DD recipients 2000–2006 |
Protocol* | 1 year | 14.4% | Mayo | 42 |
| Cosio et al | LD and DD recipients 1999–2010 LD=78% |
Protocol | 1 year | 86/935 9.5%† |
Mayo | 11 |
| Ho et al | LD and DD recipients | Protocol | 2 years | 28/111 25%‡ |
Mayo | 56 |
| Ho et al | LD and DD recipients | Protocol | 6 mos | 22/94 23.4% |
Mayo | 56 |
| TMAKP | LD and DD recipients | Protocol | 6 mos | 48/222 21.6% |
Mayo | |
| TMAKP | LD and DD recipients | Protocol | 6 mo | Pure IFTA alone (ci+ct ≥2)§ 93/222 41.9% |
||
| García-Carro et al | LD and DD recipients | Protocol | 6 wks | 108/598 18.1% |
Oslo | 43 |
| García-Carro et al | LD and DD recipients | Protocol | 1 year | 125/588¶ 21.25% |
Oslo | 43 |
The most recent Banff classification has been revised to include i-IFTA as part of chronic active TCMR. Prevalence estimates for IFTA + inflammation were used, as prior to February 2018, there was no internationally accepted definition for IFTA + inflammation. The primary composite outcome for i-IFTA will be measured using the new Banff schema.37
*They did not explicitly state that the 1 year 14.4% reported IFTA + inflammation was from protocol biopsies, but based on their treatment protocols, it is assumed to be largely protocol biopsies.
†Reported as 9.5%, but calculated as 9.2%.
‡It is anticipated that later protocol biopsies would have higher rates of IFTA + inflammation, based on 1, 3, 5-year biopsy data from Gago et al.42
§Only 16 cases met the ‘conservative criteria for IFTA + inflammation’: ci +ct ≥2, i>0 (16/222, 7.2%). The whole table is otherwise scored with the Mayo clinic criteria for IFTA + inflammation.
¶Personal communication: Daniel Serón, Clara García-Carro and Anna Reisaeter.
DD, deceased donor; LD, living donor; mo, month; TCMR, T-cell mediated rejection; TMAKP, Transplant Manitoba Adult Kidney Program; wks, weeks.